Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H32N2.2C4H5O6 |
Molecular Weight | 538.5858 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O[C@H]([C@@H](O)C([O-])=O)C(O)=O.O[C@H]([C@@H](O)C([O-])=O)C(O)=O.C[N+]2(CCCCC[N+]1(C)CCCC1)CCCC2
InChI
InChIKey=HSMKTIKKPMTUQH-WBPXWQEISA-L
InChI=1S/C15H32N2.2C4H6O6/c1-16(12-6-7-13-16)10-4-3-5-11-17(2)14-8-9-15-17;2*5-1(3(7)8)2(6)4(9)10/h3-15H2,1-2H3;2*1-2,5-6H,(H,7,8)(H,9,10)/q+2;;/p-2/t;2*1-,2-/m.11/s1
Molecular Formula | C4H6O6 |
Molecular Weight | 150.0868 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Molecular Formula | C15H32N2 |
Molecular Weight | 240.428 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Pentolinium (brand name Ansolysen) is a ganglionic cholinergic antagonist, acting on alpha 3 beta 4 neuronal nicotinic acetylcholine receptors (nAChRs). It was used as an antihypertensive drug during surgery or to control hypertensive crises, but Ansolysen was discontinued. Pentolinium inhibits release of adrenaline and noradrenaline from adrenergic nerves.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13316673
Curator's Comment: In 1952, Libman, Pain and Slack in the laboratories of May & Baker, London
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907594 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7761270 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ANSOLYSEN Approved UseUnknown |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
Other AEs: Dizziness, Constipation... Other AEs: Dizziness Sources: Constipation Vomiting Paralytic ileus (grade 5) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Constipation | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Dizziness | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Vomiting | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
|
Paralytic ileus | grade 5 | 80 mg 3 times / day multiple, intravenous Dose: 80 mg, 3 times / day Route: intravenous Route: multiple Dose: 80 mg, 3 times / day Sources: |
unhealthy, 58 years n = 1 Health Status: unhealthy Condition: hypertension Age Group: 58 years Sex: M Population Size: 1 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Noradrenaline and the kidney: friends or foes? | 2001 Dec |
|
Regional haemodynamic responses to the cannabinoid agonist, WIN 55212-2, in conscious, normotensive rats, and in hypertensive, transgenic rats. | 2001 Jun |
|
Sympathetic blockade significantly improves cardiovascular alterations immediately after spinal cord injury in rats. | 2002 Feb 15 |
|
Central cardiovascular action of urotensin II in conscious rats. | 2003 Jan |
|
Ghrelin acts at the nucleus of the solitary tract to decrease arterial pressure in rats. | 2004 May |
|
Peptide YY administration into the posterior hypothalamic nucleus of the rat evokes cardiovascular changes by non-adrenergic, non-cholinergic mechanisms. | 2005 Apr |
|
Release of acetylcholine to raise insulin secretion in Wistar rats by oleanolic acid, one of the active principles contained in Cornus officinalis. | 2006 Aug 14 |
|
Pressor effects of noradrenaline injected into the lateral septal area of unanesthetized rats. | 2006 Nov 29 |
|
Total peripheral resistance responsiveness during the development of secondary renal hypertension in dogs. | 2007 Mar |
|
Cardiovascular effects of L-glutamate microinjection in the supraoptic nucleus of unanaesthetized rats. | 2007 May |
|
Angiotensin II-based hypertension and the sympathetic nervous system: the role of dose and increased dietary salt in rabbits. | 2007 Sep |
|
Cardiovascular responses to noradrenaline microinjection in the ventrolateral periaqueductal gray of unanesthetized rats. | 2008 Feb 15 |
|
Release of acetylcholine by syringin, an active principle of Eleutherococcus senticosus, to raise insulin secretion in Wistar rats. | 2008 Mar 28 |
|
Neuronal source of plasma dopamine. | 2008 Nov |
|
Angiotensin converting enzyme-regulated, noncholinergic sympathoadrenal catecholamine release mediates the cardiovascular actions of human 'new pressor protein' related to coagulation beta-factor XIIa. | 2009 Apr |
|
Role of N-methyl-D-aspartate and non-N-methyl-D-aspartate receptors in the cardiovascular effects of L-glutamate microinjection into the hypothalamic paraventricular nucleus of unanesthetized rats. | 2009 Jul |
|
Enhanced responses to ganglion blockade do not reflect sympathetic nervous system contribution to angiotensin II-induced hypertension. | 2009 Sep |
|
Cardiovascular effects of noradrenaline microinjection into the medial part of the superior colliculus of unanesthetized rats. | 2009 Sep 22 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13316673
intramuscularly: 1 to 2 0.25-mg ampoules
Ansolysen must be used with caution. The initial dose is from 20-40 mg., taken 15 to 20 minutes before each meal and at bedtime, to ensure an even digestive absorption. Each dose is increased by 20-40 mg. four times a day at intervals of five to seven days until the desired hvpotensive effect is obtained. The maintenance dose varies generally between 160 and 800 mg. a day.
Route of Administration:
Other
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:41:20 UTC 2023
by
admin
on
Wed Jul 05 22:41:20 UTC 2023
|
Record UNII |
953357GACY
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
||
|
NCI_THESAURUS |
C66886
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
759890
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
953357GACY
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
5849
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
SUB09700MIG
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
M8515
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID5045542
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
C66345
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
DBSALT000236
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
D010425
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
55326
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
52-62-0
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
100000082536
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
200-146-7
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
CHEMBL1271
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY | |||
|
330
Created by
admin on Wed Jul 05 22:41:20 UTC 2023 , Edited by admin on Wed Jul 05 22:41:20 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE | |||
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |